Search
Immunic Inc
IMUXAdd to Watchlist
11.660USD
-0.420-3.48%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
158.83MMarket Cap
LossP/E TTM
More Details of Immunic Inc Company
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Immunic Inc Info
Ticker SymbolIMUX
Company nameImmunic Inc
IPO dateApr 17, 2014
CEOVitt (Daniel)
Number of employees91
Security typeOrdinary Share
Fiscal year-endApr 17
Address1200 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone13322559818
Websitehttps://imux.com/
Ticker SymbolIMUX
IPO dateApr 17, 2014
CEOVitt (Daniel)
Company Executives of Immunic Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
39.19K
--
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
9.55K
--
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
3.60K
--
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
1.25K
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Tamar D. Howson
Ms. Tamar D. Howson
Independent Director
Independent Director
--
--
Mr. Barclay A. (Buck) Phillips
Mr. Barclay A. (Buck) Phillips
Lead Independent Director
Lead Independent Director
--
--
Ms. Jessica Breu
Ms. Jessica Breu
Vice President - Investor Relations and Communications
Vice President - Investor Relations and Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
39.19K
--
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
20.00K
--
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
9.55K
--
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
3.60K
--
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
1.25K
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
abrdn Inc.
6.05%
BVF Partners L.P.
5.90%
Millennium Management LLC
5.83%
Avidity Partners Management LP
4.92%
Vanguard Capital Management, LLC
3.77%
Other
73.54%
Shareholders
Shareholders
Proportion
abrdn Inc.
6.05%
BVF Partners L.P.
5.90%
Millennium Management LLC
5.83%
Avidity Partners Management LP
4.92%
Vanguard Capital Management, LLC
3.77%
Other
73.54%
Shareholder Types
Shareholders
Proportion
Hedge Fund
31.12%
Investment Advisor/Hedge Fund
8.73%
Investment Advisor
7.85%
Research Firm
1.75%
Individual Investor
0.97%
Venture Capital
0.49%
Bank and Trust
0.07%
Other
49.02%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
137
58.68M
57.65%
+22.27M
2025Q4
130
58.95M
49.01%
+2.46M
2025Q3
128
47.68M
48.33%
-7.09M
2025Q2
135
50.98M
53.18%
-8.45M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
abrdn Inc.
8.24M
6.32%
--
--
Dec 31, 2025
BVF Partners L.P.
7.59M
5.82%
-62.28K
-0.81%
Feb 20, 2026
Millennium Management LLC
3.42M
2.62%
+2.89M
+544.58%
Dec 31, 2025
Avidity Partners Management LP
4.70M
3.6%
--
--
Dec 31, 2025
Soleus Capital Management, L.P.
4.50M
3.45%
+4.50M
--
Feb 17, 2026
Nantahala Capital Management, LLC
4.38M
3.36%
+4.38M
--
Dec 31, 2025
Laurion Capital Management LP
3.88M
2.98%
+2.00M
+106.26%
Dec 31, 2025
Alyeska Investment Group, L.P.
3.75M
2.87%
+3.75M
--
Dec 31, 2025
Focus Partners Wealth, LLC
2.62M
2.01%
+40.88K
+1.58%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 14, 2026
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Apr 14, 2026
Merger
10→1
